{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-043500","form_type":"8-K","ticker":"PRME","cik":"0001894562","company_name":"Prime Medicine, Inc.","filed_at":"2024-10-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.285518+00:00","generated_at":"2026-05-30T10:40:59.418811+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Prime Medicine reports up to 80% gene correction in Wilson's Disease; on track for IND-enabling","bullets":["GalNAc-LNP delivery of Prime Editors achieved up to 80% precise correction of ATP7B H1069Q mutation in humanized mice.","In NHPs, up to 51% precise editing of liver cells with surrogate H1069Q Prime Editor; no off-target edits detected.","IND-enabling activities for Wilson's Disease program to start in 4Q 2024; IND/CTA filing expected 1H 2026.","GSD1b program data: up to 85% precise liver cell editing in NHPs, durable to 44 weeks, no safety concerns.","Universal liver-targeted LNP platform shows modularity; can be adapted to other rare and non-rare liver indications."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-043500","json":"https://secwatch.observer/filing/0001628280-24-043500.json","markdown":"https://secwatch.observer/filing/0001628280-24-043500.md","text":"https://secwatch.observer/filing/0001628280-24-043500.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1894562/000162828024043500/0001628280-24-043500-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1894562/000162828024043500/prme-20241024.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T10:40:59.418811+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}